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Abstract
Purpose The roles of folate and vitamin B12 in prostate cancer (PCa) or breast cancer (BC) development are unclear. We 
investigated their roles using the prospective Swedish Apolipoprotein MOrtality RISk (AMORIS) study.
Methods 8,783 men and 19,775 women with vitamin B12 and folate serum measurements were included. Their associations 
with PCa and BC risk categories were evaluated using Cox proportional hazards regression.
Results During mean follow-up of 13  years, 703 men developed PCa. There was an inverse association between 
folate > 32 nmol/L and high-risk PCa [hazard ratio (HR) 0.12, 95% confidence interval (CI) 0.02–0.90], and a positive asso-
ciation between folate < 5 nmol/L and metastatic PCa (HR 5.25, 95% CI 1.29–21.41), compared with folate 5–32 nmol/L. No 
associations with vitamin B12 were found. 795 women developed BC during mean follow-up of 14 years. When restricting 
to the fasting population, there was a positive association between folate > 32 nmol/L and BC (HR 1.47, 95% CI 1.06–2.04).
Conclusion High folate levels may protect against PCa and low folate levels may increase risk of metastatic PCa. High fast-
ing folate levels may be associated with an increased BC risk. Vitamin B12 was not found to be linked with risk of PCa or 
BC. Longitudinal studies with serum and dietary information could help define new prevention targets and add information 
on the role of folate fortification.
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Introduction
Folate and vitamin B12 are important for cell growth and 
division. Abnormal levels of these vitamins have long 
been associated with the development of several malignan-
cies, such as colorectal [1, 2], pancreatic [3], lung [4] and 
cervix cancer [5]. Their potential role in carcinogenesis 
is thought to be due to their part in the so-called “one-
carbon metabolism pathway”. This pathway is important 
for DNA synthesis, repair and methylation [6]. Epigenetic 
changes such as DNA hypo and hypermethylation, DNA 
uracil misincorporation, and chromosomal rearrangements 
have been seen in many tumour tissues, including prostate 
cancer (PCa) [7–9] and breast cancer (BC) [10]. This sug-
gests that altered levels of these vitamins could potentially 
promote cancer development.
Some studies have investigated the association between 
folate, vitamin B12 and the risks of PCa and BC, with 
inconsistent results. Among other studies [11, 12], a Nor-
wegian nested case–control study, which included 3,000 
cases and 3,000 controls with blood samples collected 
between 1973 and 2004, suggested that high levels of 
serum folate increase the risk of PCa [13]. A prospective 
case–control study which included 29,133 male smok-
ers aged 50–69 years in Finland between 1985 and 1988 
did, however, not find any association between serum 
folate levels and PCa [14]. In another nested case–con-
trol study, which included 6,875 cases and 8,104 controls, 
with blood samples collected between 1981 and 2008 and 
with an average follow-up of 8.9 years, high folate lev-
els were associated with an enhanced risk of high grade 
PCa, suggesting that folate may play a role in the progres-
sion of PCa [11]. In contrast, an Australian prospective 
cohort study, which included 964 men with a follow-up of 
20 years, found that decreased folate levels increased PCa 
mortality risk [15]. Vitamin B12 has, as well as folate, 
been associated with the increased PCa risk in some stud-
ies [11, 12]. A prospective Swedish study found that vita-
min B12 may be associated with up to a threefold increase 
in PCa risk [16]. Yet, the previously mentioned Finnish 
study also looked at vitamin B12 and found no association 
between vitamin B12 and PCa.
For BC, both positive and negative associations have 
been found between serum folate levels and BC risk. Stud-
ies have suggested that high folate levels are associated 
with the increased BC risk in women with BRCA1/2 muta-
tions [17] and also in women with estrogen receptor beta 
negative BC [18]. The first study was a prospective study 
which included 164 women with BRCA1/2 mutations in 
Canada, whereas the second study was a Swedish nested 
case–control study which included 204 cases and 408 con-
trols. Conversely, another prospective nested case–control 
study in the US, with 712 cases and controls, found that 
high folate levels may reduce the risk of BC, especially 
in women with high alcohol consumption [19]. Studies 
on the effects of vitamin B12 on BC risk have also been 
inconclusive. A weak positive association between vitamin 
B12 levels and BC risk in women who had a high con-
sumption of alcohol was found in one nested case–control 
study, which included 2,491 cases and 2,521 controls from 
Europe [20]. However, another US nested case–control 
study with 195 cases and controls found that low B12 lev-
els may increase the risk of BC [21], whereas an additional 
US nested case–control study with 848 cases and controls 
found no association [22].
In this study, we investigated the associations between 
serum folate, vitamin B12, and risks of PCa and BC further 
by including information on tumour characteristics.
Materials and methods
Study population and data collection
All data were obtained from the Swedish Apolipoprotein-
related MOrtality RISk (AMORIS) cohort. This database 
contains blood samples from 812,073 individuals who 
mainly came from the greater Stockholm area and were 
either having a general health check-up or were outpatients 
referred for laboratory testing. None of the participants were 
inpatients at the time of the blood sampling. The blood sam-
ples were analysed and evaluated in the Central Automation 
Laboratory (CALAB) in Stockholm, Sweden, from 1985 to 
1996. In the AMORIS cohort, the CALAB database was 
linked to several Swedish national registries such as the 
Swedish National Cancer Register, the Hospital Discharge 
Register, the Cause of Death Register, the consecutive Swed-
ish Censuses from 1970 to 1990, and the National Register 
of Emigration using the Swedish 10-digit personal identity 
number. These resources provided complete follow-up infor-
mation until death or the end of December 2011. A more 
detailed description of the AMORIS cohort can be found 
elsewhere [23]. The study complies with the Declaration 
of Helsinki, and the Ethics Review Board of the Karolinska 
Institute has approved the study [23].
In this study, we particularly used the Swedish National 
Cancer Register [24], to which reporting is mandated, the 
National Prostate Cancer Register (NPCR) [25] and the 
Stockholm Clinical Quality Register for Breast Cancer [26, 
27], to extract information about the cancer diagnoses. 
The NPCR includes 98% of all newly diagnosed PCa cases 
in the Swedish National Cancer Register. It was estab-
lished to provide data for quality assurance and has been 
offering the service nationwide since 1998 [25, 28]. We 
used data on date of diagnosis, age at diagnosis, serum 
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concentration of PSA at time of diagnosis, TNM stage and 
Gleason score from the NPCR. The Stockholm Clinical 
Quality Register for Breast Cancer started in 1976 and is 
considered to have 97% coverage having been cross ref-
erenced with the Swedish National Cancer Register. This 
register was established to record the quality of care based 
on regional or national guidelines for BC management. 
Individual information about date of diagnosis, detection 
mode, tumour characteristics, pathological tumour-stage 
and treatment for all the newly diagnosed BC patients has 
been reported continuously by clinicians to the register. 
To evaluate current vital status of the registered patients, 
the register is also updated regularly against the National 
Population Register [26, 29].
We included all men aged 30 years and older and all 
women aged 20 years and older. All included participants 
had baseline serum measurements for both folate and vita-
min B12 and were not diagnosed with PCa or BC at the time 
of inclusion. Only those with a diagnosis of invasive BC 
were included in the BC study due to lack of information on 
non-invasive BCs. Follow-up time was defined as time from 
baseline serum measurement until date of PCa or invasive 
BC diagnosis, death, emigration or study closing time (31 
December 2011)—whichever occurred earlier.
Information on comorbidity was obtained by means of the 
Charlson comorbidity index (CCI). The CCI accounts for 19 
diseases, and each disease is assigned a certain number of 
points. The sum of these points gives a score on which dif-
ferent comorbidity levels are created, from no comorbidity 
to severe comorbidity (0, 1, 2, ≥ 3) [30]. CCI was calculated 
by using information obtained from the National Patient 
Register. Data on educational levels were taken from the 
Population and Housing Census for the period 1970–1990. 
Socioeconomic status (SES) was based on occupational sta-
tus and categorised gainfully employed individuals into blue 
and white collar workers and into manual or non-manual 
employees [31]. In addition, the CALAB database contained 
information on age and fasting status at time of blood sam-
pling. All other information was extracted from the registries 
previously mentioned.
The main exposures of interest were serum levels of folate 
and vitamin B12. We used reference ranges from the Karo-
linska Hospital, Stockholm, Sweden to divide these into 
categories [32, 33]. Serum folate levels were categorised 
as low (< 5 nmol/L), normal (5–32 nmol/L) and high levels 
(> 32 nmol/L). Vitamin B12 serum levels were equally cat-
egorised into low (< 150 pmol/L), normal (150–650 pmol/L) 
and high levels (> 650 pmol/L). Serum folate was measured 
by means of a competitive assay in which folate from the 
patient sample competes with the Lite Reagent. Serum vita-
min B12 was measured by means of a competitive chemi-
luminescent sandwich assay in which vitamin B12 from the 
patient sample competes with the Lite Reagent [23].
In addition, we used information on a variety of biomark-
ers which may be potential confounders for the associations 
between vitamin B12, folate, and risk of PCa or BC. Total 
cholesterol and triglycerides were measured enzymatically 
[34], and serum glucose was also measured enzymatically 
with a glucose/peroxidase method [35]. Serum iron was 
measured via acidification with citric acid in order to dis-
sociate the  Fe3+-transferring complex (coefficient of vari-
ation < 5%) [36]. A colorimetric method was used for the 
measurement of total serum calcium (coefficient of varia-
tion < 2.5%) [37]. Gamma-glutamyl transferase (GGT) was 
also measured by an enzymatic colorimetric method [38]. 
All methods were fully automated with automatic calibra-
tion and performed at the same accredited laboratory [35].
With respect to outcomes, we defined PCa based on 
risk categories (low risk, intermediate risk, high risk and 
regional/distant metastatic) by means of PSA, Gleason score 
and TNM stage [25]. “Low risk” was defined as T1–2, Glea-
son score 2–6 and PSA < 10 ng/mL; “intermediate risk” 
as T1–2, Gleason score 7 and/or PSA 10 to < 20 ng/mL; 
“high risk” as T3 and/or Gleason score 8–10 and/or PSA 
20 to < 50 ng/mL “regionally metastatic tumours” as T4 
and/or N1 and/or PSA 50 to < 100 ng/mL in the absence 
of distant metastases (M0 or MX); and “distant metastatic 
tumours” were defined as M1 and/or PSA > 100 ng/mL and/
or death within 4 years after PCa diagnosis, where PCa was 
the cause of death. As well as looking at risk categories, we 
looked at some clinicopathological features separately (PSA 
levels, Gleason score and TNM stage). PSA concentrations 
were classified as < 4 μg/L, 4.0–9.9 μg/L, 10.0–20.0 μg/L 
and > 20.0 μg/L. Gleason score was categorised as Gleason 
score ≤ 6 or WHO grade 1; Gleason score 7 or WHO grade 
2; and Gleason score ≥ 8 or WHO grade 3 [28].
BC was also divided into risk categories (good, moderate 
and severe) based on age, estrogen receptor status, and TNM 
stage [29]. “Good” was defined as ER+ or ER− and pTNM 
stage I, “Moderate” as ER+, age > 40 years and pTNM 
stage II, “Severe” as age < 40 years and pTNM stage II or 
ER− and pTNM stage II or pTNM stage III or IV. HER2 
status could not be included due to a lack of information.
Data analysis
All data were analysed with Statistical Analysis Software 
(SAS) release 9.4. Cox proportional hazard regression mod-
els were used to estimate hazard ratios (HRs) and 95% confi-
dence intervals (CIs) for the risk of developing PCa and BC 
based on serum levels of vitamin B12 and folate. HRs were 
estimated for the overall PCa and BC risk as well as for PCa 
and BC risk categories.
The multivariate models included covariates for age, 
education level (low, medium, high), SES (low, high), CCI 
(0, 1, 2, ≥ 3), serum glucose, triglycerides, cholesterol and 
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fasting status (fasting, non-fasting). Information about BMI 
was missing for a large part of the study population and 
was therefore not included in the multivariate adjustments. 
To compensate for the lack of information regarding BMI, 
we adjusted for triglycerides and cholesterol. Studies have 
shown that overweight people are more likely to have higher 
total cholesterol [39] and higher triglycerides than non-over-
weight people [40].
We also conducted further sensitivity analyses by add-
ing GGT, iron and calcium in the model. Iron and calcium 
were added as some of the sources for these minerals are the 
same sources as for folate and vitamin B12 and they could 
therefore be potential confounders [41, 42]. Furthermore, 
calcium has been associated with PCa risk in some studies 
[14]. GGT was added since we did not have information 
about alcohol consumption and alcohol may have an impact 
on folate levels [15]. In addition, alcohol has been linked 
to many cancer types, including PCa and BC [43]. GGT is 
one of the biomarkers that is widely used for indication of 
a patient’s alcohol intake. Several weeks of high intake of 
alcohol give rise to raised GGT levels [44].
Moreover, we conducted a sensitivity analysis exploring 
the fasting status including only the participants that were 
fasting at time of blood drawn. We also conducted further 
analysis using the continuous log value of folate and vita-
min B12 instead of the categorical groups. Additionally, we 
looked at reverse causation by excluding those who had a 
follow-up smaller than 3 years.
Results
A total number of 8,783 men were included. Most of the men 
had normal B12 (150–650 pmol/L) and folate (5–32 nmol/L) 
levels (90.7% and 91.4%, respectively). All characteristics of 
the male study population are shown in Table 1. About 703 
individuals developed PCa during a mean follow-up time of 
12.7 years (± 6.2 SD). All characteristics of the PCa cases 
are shown in Table 2. Some differences between the expo-
sure groups can be found for the main categorical variables 
studied. 
HRs and 95% CI for the association between vitamin B12, 
folate and PCa risk categories are shown in Table 3. An 
inverse statistically significant association between folate 
levels > 32 nmol/L and high-risk PCa was seen (HR 0.12, 
95% CI 0.02–0.90), compared to folate levels between 5 and 
32 nmol/L. There was also a statistically significant posi-
tive association between regional/distant metastatic PCa and 
folate levels < 5 nmol/L (HR 4.12, 95% CI 1.01–16.82). For 
metastatic PCa, this association could not be analysed multi-
variately due to low number of cases. No statistically signifi-
cant associations were found between vitamin B12 and PCa 
risk categories. Restricting the study population to fasting 
men only did not result in statistically significant findings 
due to a smaller sample size (Supplemental Table 1). How-
ever, the observed trends remained the same.
A total of 19,775 women were included in the study. Dur-
ing a mean follow-up time of 14.3 years (± 5.4 SD), 795 
individuals developed BC. Most women had normal B12 and 
folate levels (89.7% and 87.9%, respectively). Further base-
line characteristics of the female study population are shown 
in Tables 4 and 5. Results from the analyses with Cox pro-
portional hazard models are shown in Table 6. We observed 
no statistically significant associations between folate, vita-
min B12 and BC in the total study population. Restricting 
the study population to fasting women only showed a posi-
tive association between high folate levels > 32 nmol/L and 
the risk of BC overall (HR 1.47, 95% CI 1.06–2.04) as well 
as “good” BC (Supplemental Table 2).  
The sensitivity analyses including additional adjustments 
for GGT, iron and calcium, as well as the sensitivity analyses 
excluding those with follow-up times less than 3 years, did 
not change the results (results not shown). No associations 
were found when using the continuous log value of the expo-
sure variables (results not shown).
Discussion
Compared with normal folate levels (5–32  nmol/L), 
an inverse association between high serum folate lev-
els (> 32 nmol/L) and high-risk PCa was seen, as well 
as a positive association between low serum folate levels 
(< 5 nmol/L) and metastatic PCa. For BC, there was no 
indication of an association with folate or vitamin B12 
in the total population. However, the fasting population 
showed a positive association between serum folate levels 
(> 32 nmol/L) and risk of BC in comparison with normal 
folate levels.
Previous literature has shown inconclusive results for the 
association between folate, vitamin B12 and the risks of PCa 
and BC. Some studies have suggested a positive association 
between folate and PCa risk [11–13], while others have not 
found a significant association [45]. This study, on the con-
trary, suggests that high folate levels may reduce the risk of 
high grade PCa. This could indicate that folate may play a 
protective role in both the development and the progression 
of PCa. Even though the case numbers of people with low 
folate levels and metastatic PCa were low, findings from 
this study also suggest that low folate levels may increase 
the risk of getting metastatic PCa. Similar to this, an Aus-
tralian study looking at folate levels and cancer morbidity 
and mortality showed that decreased folate levels increased 
the risk of PCa mortality [46]. These findings suggest that 
folate may potentially be a target nutrient for preventing PCa 
development and progression.
Cancer Causes & Control 
1 3
Our mean follow-up time in the PCa cohort was 
12.7 years (± 6.2 SD), which is longer than one of the stud-
ies with different results [11], but shorter than another study 
with contradictory results [13]. Hence, differences in results 
between these two studies and our study are unlikely to be 
due to different lengths in follow-up times. Similarly, it 
is unlikely that these observations explain the differences 
between our findings and other studies for the association 
between vitamin B12 and PCa risk [11, 12].
For BC, some studies have found that high folate levels 
may enhance the risk of some types of BC [17, 18], which 
was also found in our fasting analysis. Conversely, another 
Table 1  Characteristics of the male study population
a–f These measurements were only recorded in some cases within the study population, with the following numbers of people (N) for each respec-
tive measurement: aN = 5,542, bN = 5,714, cN = 5,681, dN = 6,194, eN = 6,613, fN = 5,827
Vitamin B12 (pmol/L) p values Folate (nmol/L) p values
< 150 150–650 > 650 < 5 5–32 > 32
(n = 279) (n = 7962) (n = 542) (n = 65) (n = 8030) (n = 688)
Age [mean 
(SD)]
65 (15.1) 60 (14.8) 64 (15.7) < 0.01 68 (15.6) 60 (14.9) 64 (15.1) < 0.01
Education [N 
(%)]
0.04 < 0.01
 Low 89 (31.9) 2,216 (27.8) 152 (28.0) 30 (46.2) 2,279 (28.4) 148 (21.5)
 Intermediate 88 (31.5) 2,974 (37.4) 198 (36.5) 14 (21.5) 3,016 (37.6) 230 (33.4)
 High 58 (20.8) 2,163 (27.2) 120 (22.1) 14 (21.5) 2,108 (26.3) 219 (31.8)
 Missing 44 (15.8) 609 (7.7) 72 (13.3) 7 (10.8) 627 (7.8) 91 (13.2)
SES [N (%)] 0.85 < 0.01
 Low 74 (26.5) 2,436 (30.6) 151 (27.9) 28 (43.1) 2,474 (30.8) 159 (23.1)
 High 122 (43.7) 4,187 (52.6) 246 (45.4) 21 (32.3) 4,153 (51.7) 381 (55.4)
 Missing 83 (29.8) 1,339 (16.8) 145 (26.8) 16 (24.6) 1,403 (17.5) 148 (21.5)
BMI [N (%)] 0.08 0.64
  < 25/ ≥ 25 17 (6.1)/11 
(3.9)
356 (4.5)/388 
(4.9)
19 (3.5)/10 
(1.9)
2 (3.1)/2 (3.1) 366 (4.6)/375 
(4.7)
24 (3.5)/32 
(4.7)
 Missing 251 (90.0) 7,218 (90.7) 513 (94.7) 61 (93.9) 7,289 (90.8) 632 (91.9)
CCI [N (%)] < 0.01 < 0.01
 0 206 (73.8) 6,205 (77.9) 348 (64.2) 38 (58.5) 6,204 (77.3) 517 (75.2)
 1 41 (14.7) 868 (10.9) 80 (14.8) 7 (10.8) 905 (11.3) 77 (11.2)
 2 18 (6.5) 508 (6.4) 59 (10.9) 14 (21.5) 519 (6.5) 52 (7.6)
 ≥ 3 14 (5.0) 381 (4.8) 55 (10.2) 6 (9.2) 402 (5.0) 42 (6.1)
Glucosea
 Median (IQR) 5.2 (4.7–5.7) 5.2 (4.8–5.8) 5.3 (4.8–6.2) 0.01 5.1 (4.7–5.7) 5.2 (4.8–5.8) 5.2 (4.8–5.9) 0.39
Total 
 cholesterolb
 Median (IQR) 5.2 (4.7–5.8) 5.7 (5.0–6.4) 5.5 (4.8–6.3) < 0.01 5.2 (4.5–6.6) 5.7 (5.0–6.4) 5.6 (4.9–6.4) 0.17
Triglyceridesc
 Median (IQR) 1.3 (1.0–1.9) 1.3 (0.9–2.0) 1.2 (0.9–1.8) 0.38 1.1 (0.9–1.8) 1.3 (0.9–2.0) 1.2 (0.9–1.9) 0.56
GGT d
 Median (IQR) 0.4 (0.3–0.7) 0.5 (0.3–0.8) 0.6 (0.3–1.4) < 0.01 0.4 (0.3–0.6) 0.5 (0.3–0.8) 0.5 (0.3–0.8) 0.17
Irone
 Median (IQR) 17 (13–21) 18 (15–22) 18 (14–22) 0.03 14.0 (12–17) 18 (15–22) 18 (15–22) 0.01
Calciumf
 Median (IQR) 2.34 (2.27–
2.42)
2.38 (2.31–
2.44)
2.38 (2.31–
2.46)
0.01 2.31 (2.24–
2.39)
2.38 (2.31–
2.44)
2.37 (2.30–
2.43)
0.01
Fasting status [N (%)] 0.01 < 0.01
 Fasting 89 (31.9) 2,700 (33.9) 193 (35.6) 6 (9.2) 2,675 (33.3) 301 (43.8)
 Nonfasting 45 (16.1) 2,386 (30.0) 129 (23.8) 11 (16.9) 2,377 (29.6) 172 (25.0)
 Missing 145 (52.0) 2,876 (36.1) 220 (40.6) 48 (73.9) 2,978 (37.1) 215 (31.3)
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study showed that high folate concentrations were inversely 
associated with BC risk [19]. For vitamin B12 and BC risk, 
one study found a weak positive association between vita-
min B12 levels and BC risk in women who had a high con-
sumption of alcohol [20] and another study found that low 
B12 levels may increase the risk of BC [21], suggesting that 
abnormal levels of B12 could lead to a higher BC risk. Yet, 
like some other studies [22], we did not find any significant 
associations between folate, vitamin B12 and BC in the total 
study population.
Our mean follow-up time in the BC cohort was 14.3 years 
(± 5.4 SD), which was longer than the follow-up time in the 
previously mentioned studies, both in those that had similar 
[17, 18, 20] and contradictory [19, 21] findings. This again 
suggests that the difference in findings is unlikely due to 
differences in follow-up time. However, it needs to be noted 
that we did observe an association between folate and BC 
risk when restricting our analyses to the fasting population—
this suggests that in addition to the need for a wide variety of 
confounders (as shown also by our own crude and multivari-
ate analyses) when analysing B12 and folate in relation to 
risk of cancer, there is a need to have clear information on 
fasting status as this may also affect the findings and hence 
explain a lot of the heterogeneity observed today.
Table 2  Characteristics of the study population with PCa
a PCa risk categories defined as low risk, intermediate risk, high risk and regional/distant metastatic based on their TNM stage, Gleason score 
and PSA levels, according to the NPCR
Vitamin B12 (pmol/L) Folate (nmol/L)
< 150
(n = 17)
150–650
(n = 648)
> 650
(n = 38)
< 5
(n = 6)
5–32
(n = 646)
> 32
(n = 51)
PSA (μg/L) median (IQR) 6.5 (4.7–11.0) 11.0 (6.0–23.0) 16.0 (6.9–30.0) 13.0 (8.3–35.0) 11.0 (6.1–23.0) 9.7 (4.7–18.0)
N (%)
 < 4 1 (5.9) 42 (6.5) 1 (2.6) 0 (0.0) 38 (5.9) 6 (11.8)
 4.0–9.9 7 (41.2) 170 (26.2) 8 (21.1) 1 (16.7) 174 (26.9) 10 (19.6)
 10.0–20.0 2 (11.8) 115 (17.8) 6 (15.8) 2 (33.3) 112 (17.3) 9 (17.7)
 > 20.0 2 (11.8) 127 (19.6) 10 (26.3) 1 (16.7) 131 (20.3) 7 (13.7)
 Missing 5 (29.4) 194 (29.9) 13 (34.2) 2 (33.3) 191 (29.6) 19 (37.3)
Gleason scores/WHO grades [N (%)]
 Gleason score ≤ 6 or WHO grade 1 7 (41.2) 210 (32.4) 12 (31.6) 2 (33.3) 206 (31.9) 21 (41.2)
 Gleason score 7 or WHO grade 2 4 (23.5) 176 (27.2) 7 (18.4) 1 (16.7) 176 (27.2) 10 (19.6)
 Gleason score ≥ 8 or WHO grade 3 1 (5.9) 71 (11.0) 7 (18.4) 0 (0.0) 76 (11.8) 3 (5.9)
 Missing 5 (29.4) 191 (29.5) 12 (31.6) 3 (50.0) 188 (29.1) 17 (33.3)
T-stages [N (%)]
 T1 7 (41.2) 194 (29.9) 8 (21.1) 2 (33.3) 190 (29.4) 17 (33.3)
 T2 4 (23.5) 148 (22.8) 10 (26.3) 0 (0.0) 153 (23.7) 9 (17.7)
 T3 2 (11.8) 93 (14.4) 8 (21.1) 2 (33.3) 93 (14.4) 8 (15.7)
 T4 0 (0.0) 15 (2.3) 0 (0.0) 0 (0.0) 15 (2.3) 0 (0.0)
 Missing 4 (23.5) 198 (30.6) 12 (31.6) 2 (33.3) 195 (30.2) 17 (33.3)
N-stages [N (%)]
 N0 1 (5.9) 35 (5.4) 0 (0.0) 0 (0.0) 36 (5.6) 0 (0.0)
 N1 0 (0.0) 11 (1.7) 1 (2.6) 0 (0.0) 10 (1.6) 2 (3.9)
 Missing 16 (94.1) 602 (92.9) 37 (97.4) 6 (100.0) 600 (92.9) 49 (96.1)
M-stages [N (%)]
 M0 2 (11.8) 138 (21.3) 4 (10.5) 1 (16.7) 136 (21.1) 7 (13.7)
 M1 0 (0.0) 27 (4.2) 3 (7.9) 1 (16.7) 26 (4.0) 3 (5.9)
 Missing 15 (88.2) 483 (74.5) 31 (81.6) 4 (66.7) 484 (74.9) 41 (80.4)
Risk  categoriesa [N (%)]
 Low risk 4 (23.5) 111 (17.1) 6 (15.8) 1 (16.7) 108 (16.7) 12 (23.5)
 Intermediate risk 4 (23.5) 125 (19.3) 5 (13.2) 1 (16.7) 126 (19.5) 7 (13.7)
 High risk 2 (11.8) 136 (21.0) 8 (21.1) 0 (0.0) 140 (21.7) 6 (11.8)
 Regional/distant metastatic 2 (11.8) 75 (11.6) 6 (15.8) 2 (33.3) 74 (11.5) 7 (13.7)
 Missing 5 (29.4) 201 (31.0) 13 (34.2) 2 (33.3) 198 (30.7) 19 (37.3)
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Table 3  Hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations between vitamin B12, folate, and PCa risk categories
Multivariate models adjusted for age, education level, SES, CCI, serum glucose, triglycerides, cholesterol and fasting status
Total population 
N = 8783
Vitamin B12 (pmol/L) p for trend Folate (nmol/L) p for trend
< 150 150–650 > 650 < 5 5–32 > 32
(n = 279) (n = 7962) (n = 542) (n = 65) (n = 8030) (n = 688) 
PCa
 N = 703 17 648 38 6 646 51
 Crude HR (95% 
CI)
0.85 (0.52–1.37) 1.00 (Ref) 1.09 (0.79–1.52) 0.77 1.77 (0.79–3.95) 1.00 (Ref) 1.01 (0.76–1.34) 0.40
 Age-adjusted 
HR (95% CI)
0.72 (0.45–1.17) 1.00 (Ref) 0.91 (0.66–1.26) 0.60 1.42 (0.63–3.16) 1.00 (Ref) 0.82 (0.62–1.09) 0.13
 Multivariate 
adjusted HR 
(95% CI)
0.92 (0.43–1.95) 1.00 (Ref) 0.99 (0.61–1.62) 0.87 NA 1.00 (Ref) 0.73 (0.48–1.10) 0.07
Risk categories
 Low risk
  N = 121 4 111 6 1 108 12
  Crude HR 
(95% CI)
1.23 (0.45–3.34) 1.00 (Ref) 1.06 (0.47–2.42) 0.76 1.94 (0.27–13.93) 1.00 (Ref) 1.47 (0.81–2.66) 0.64
  Age-adjusted 
HR (95% CI)
1.18 (0.43–3.20) 1.00 (Ref) 1.02 (0.45–2.33) 0.77 1.87 (0.26–13.43) 1.00 (Ref) 1.38 (0.76–2.50) 0.74
  Multivariate 
adjusted HR 
(95% CI)
1.07 (0.26–4.38) 1.00 (Ref) 0.85 (0.27–2.69) 0.75 NA 1.00 (Ref) 1.39 (0.68–2.78) 0.99
 Intermediate risk
  N = 135 4 126 5 1 127 7
  Crude HR 
(95% CI)
1.06 (0.39–2.88) 1.00 (Ref) 0.80 (0.33–1.94) 0.80 1.74 (0.24–12.45) 1.00 (Ref) 0.72 (0.34–1.55) 0.68
  Age-adjusted 
HR (95% CI)
0.97 (0.36–2.64) 1.00 (Ref) 0.73 (0.30–1.77) 0.81 1.58 (0.22–11.33) 1.00 (Ref) 0.63 (0.29–1.35) 0.91
  Multivariate 
adjusted HR 
(95% CI)
1.41 (0.34–5.80) 1.00 (Ref) 1.50 (0.60–3.72) 0.15 NA 1.00 (Ref) 0.52 (0.19–1.42) 0.98
 High risk
  N = 147 2 137 8 0 141 6
  Crude HR 
(95% CI)
0.47 (0.12–1.91) 1.00 (Ref) 1.13 (0.55–2.30) 0.47 NA 1.00 (Ref) 0.55 (0.24–1.24) 0.01
  Age-adjusted 
HR (95% CI)
0.40 (0.10–1.61) 1.00 (Ref) 0.92 (0.45–1.88) 0.59 NA 1.00 (Ref) 0.43 (0.19–0.98) 0.01
  Multivariate 
adjusted HR 
(95% CI)
NA 1.00 (Ref) 0.24 (0.03–1.72) 0.78 NA 1.00 (Ref) 0.12 (0.02–0.90) 0.01
 Regional/distant metastatic
  N = 85 2 77 6 2 76 7
  Crude HR 
(95% CI)
0.84 (0.21–3.40) 1.00 (Ref) 1.47 (0.64–3.37) 0.98 5.25 (1.29–21.41) 1.00 (Ref) 1.18 (0.54–2.55) 0.28
  Age-adjusted 
HR (95% CI)
0.68 (0.17–2.75) 1.00 (Ref) 1.12 (0.49–2.59) 0.87 4.12 (1.01–16.82) 1.00 (Ref) 0.90 (0.41–1.95) 0.19
  Multivariate 
adjusted HR 
(95% CI)
1.55 (0.21–11.61) 1.00 (Ref) 0.66 (0.09–4.92) 0.12 NA 1.00 (Ref) 1.09 (0.33–3.60) 0.23
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Results from studies exploring dietary intake of folate 
and vitamin B12 and PCa and BC risk, often seem to have 
diverse results compared to studies of serum concentrations 
of folate and vitamin B12. Adequate folate intake has been 
suggested to protect against BC [47–51], whereas in many 
studies serum folate has been suggested to have a positive 
association with BC risk which is also supported by our find-
ings from the fasting analysis [17, 18]. Equally, an inverse 
association between folate intake and PCa risk has been 
seen [52, 53], while serum folate has been positively asso-
ciated with PCa risk [11–13]. Therefore, studies analysing 
both dietary intake and serum concentrations are needed, to 
Table 4  Characteristics of the female study population
a–f These measurements were only recorded in some cases within the study population, with the following numbers of people (N) for each respec-
tive measurement: aN = 11,765, bN = 12,005, cN = 11,936, dN = 12,934, eN = 15,065, fN = 1,271
Vitamin B12 (pmol/L) p values Folate (nmol/L) p values
< 150 150–650 > 650 < 5 5–32 > 32
(n = 549) (n = 17,731) (n = 1,495) (n = 116) (n = 17,389) (n = 2,270)
Age [mean 
(SD)]
58 (20.2) 55 (18.1) 63 (17.3) < 0.01 61 (20.1) 55 (18.3) 61 (17.2) < 0.01
Education [N 
(%)]
< 0.01 0.01
 Low 173 (31.5) 5,095 (28.7) 493 (33.0) 36 (31.0) 5,091 (29.3) 634 (27.9)
 Intermediate 189 (34.4) 7,038 (39.7) 487 (32.6) 50 (43.1) 6,855 (39.4) 809 (35.6)
 High 104 (18.9) 4,244 (23.9) 318 (21.3) 13 (11.2) 4,070 (23.4) 583 (25.7)
 Missing 83 (15.1) 1,354 (7.6) 197 (13.2) 17 (14.7) 1,373 (7.9) 244 (10.8)
SES [N (%)] 0.01 < 0.01
 Low 206 (37.5) 7,780 (43.9) 494 (33.0) 53 (45.7) 7,613 (43.8) 814 (35.9)
 High 121 (22.0) 5,266 (29.7) 406 (27.2) 17 (14.7) 5,068 (29.1) 708 (31.2)
 Missing 222 (40.4) 4,685 (26.4) 595 (39.8) 46 (39.7) 4,708 (27.1) 748 (33.0)
BMI [N (%)] 0.89 0.24
  < 25/≥ 25 27 (4.9)/12 
(2.2)
1,064 (6.0)/518 
(2.9)
72 (4.8)/38 
(2.5)
9 (7.8)/1 (0.9) 1,023 (5.9)/509 
(2.9)
131 (5.8)/58 
(2.6)
 Missing 510 (92.9) 16,149 (91.1) 1,385 (92.6) 106 (91.4) 15,857 (91.2) 2,081 (91.7)
CCI [N (%)] < 0.01 < 0.01
 0 449 (81.8) 14,965 (84.4) 1,107 (74.1) 81 (69.8) 14,586 (83.9) 1,854 (81.7)
 1 50 (9.1) 1,348 (7.6) 192 (12.8) 14 (12.1) 1,392 (8.0) 184 (8.1)
 2 31 (5.7) 970 (5.5) 99 (6.6) 11 (9.5) 922 (5.3) 167 (7.4)
 ≥ 3 19 (3.5) 448 (2.5) 97 (6.5) 10 (8.6) 489 (2.8) 65 (2.9)
Glucosea
 Median (IQR) 4.8 (4.4–5.2) 4.9 (4.5–5.4) 4.9 (4.6–5.5) < 0.01 5.0 (4.7–5.4) 4.9 (4.5–5.4) 4.9 (4.5–5.4) 0.11
Total  cholesterolb
 Median (IQR) 5.5 (4.7–6.5) 5.7 (4.9–6.6) 5.9 (5.1–6.7) 0.01 5.5 (5.0–6.1) 5.7 (4.9–6.6) 5.9 (5.1–6.7) 0.01
Triglyceridesc
 Median (IQR) 1.1 (0.8–1.6) 1.0 (0.7–1.5) 1.1 (0.8–1.6) 0.38 1.3 (1.0–2.0) 1.1 (0.7–1.5) 1.0 (0.7–1.5) 0.11
GGT d
 Median (IQR) 0.3 (0.2–0.4) 0.3 (0.2–0.5) 0.3 (0.2–0.6) < 0.01 0.3 (0.2–0.7) 0.3 (0.2–0.5) 0.3 (0.2–0.5) 0.85
Irone
 Median (IQR) 15 (12–20) 17 (13–21) 17 (13–20) 0.01 15 (10–19) 17 (13–21) 17 (14–21) < 0.01
Calciumf
 Median (IQR) 2.34 (2.23–
2.42)
2.37 (2.31–
2.44)
2.39 (2.32–
2.45)
< 0.01 2.32 (2.23–
2.39)
2.37 (2.30–
2.44)
2.38 (2.32–
2.44)
< 0.01
Fasting status 
[N (%)]
0.11 0.01
 Fasting 183 (33.3) 5,633 (31.8) 472 (31.6) 20 (17.2) 5,395 (31.0) 873 (38.5)
 Non-fasting 126 (23.0) 4,947 (27.9) 403 (27.0) 24 (20.7) 4,818 (27.7) 634 (27.9)
 Missing 240 (43.7) 7,150 (40.3) 620 (41.5) 72 (62.1) 7,175 (41.3) 763 (33.6)
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determine whether findings from studies examining serum 
concentrations would be applicable to dietary intake.
Some countries have introduced mandatory folate forti-
fication to prevent neural tube defects in newborn babies, 
whereas others have been more restrictive because of the 
limited knowledge about how folate affects cancer [54]. 
In Sweden, there is no mandatory fortification [55]. A few 
products are, however, frequently fortified such as cereal and 
juice [56]. The different policies in folate fortification could 
be another factor explaining variations in studies performed 
in different countries.
Categorisation of folate distributions may be another 
factor explaining potential differences between studies. We 
divided the population into three different groups depending 
on whether they had low, normal or high serum levels, based 
on the reference levels used in Swedish clinics. Other stud-
ies, on the other hand, have looked at quartiles or quintiles of 
serum levels [11, 13, 45]. Nevertheless, the trends observed 
in the various studies were different.
An important strength of this study was the large study 
population and the prospective measurements of serum con-
centrations of folate and vitamin B12. All blood tests were 
analysed at the same clinical laboratory (CALAB) and the 
analyses were performed on fresh blood. Furthermore, the 
blood tests were taken in outpatients and there is no indica-
tion that they were taken on the basis of disease symptoms. 
Each person in this study had a complete follow-up time 
and the linkage with other national registers provided good 
Table 5  Characteristics of the study population with BC
Vitamin B12 (pmol/L) Folate (nmol/L)
< 150
(n = 12)
150–650
(n = 725)
> 650
(n = 58)
< 5
(n = 3)
5–32
(n = 687)
> 32
(n = 105)
Parity [N (%)]
 Yes/no 9 (75.0)/3 (25.0) 546 (75.3)/179 (24.7) 45 (77.6)/13 (22.4) 1 (33.3)/2 (66.7) 524 (76.3)/163 (23.7) 75 (71.4)/30 (28.6)
Tumour side [N (%)]
 Right/left 5 (41.7)/5 (41.7) 294 (40.6)/338 (46.6) 33 (56.9)/18 (31.0) 2 (66.7)/1 (33.3) 281 (40.9)/317 (46.1) 49 (46.7)/43 (41.0)
 Missing 2 (16.7) 93 (12.8) 7 (12.1) 0 (0.0) 89 (13.0) 13 (12.4)
Invasive grades [N (%)]
 Grade 1 0 (0.0) 41 (5.7) 7 (12.1) 0 (0.0) 42 (6.1) 6 (5.7)
 Grade 2 3 (25.0) 147 (20.3) 11 (19.0) 1 (33.3) 140 (20.4) 20 (19.1)
 Grade 3 2 (16.7) 71 (9.8) 2 (3.5) 0 (0.0) 67 (9.8) 8 (7.6)
 Missing 7 (58.3) 466 (64.3) 38 (65.5) 2 (66.7) 438 (63.8) 71 (67.6)
T-stages [N (%)]
 T1 6 (50.0) 425 (58.6) 28 (48.3) 2 (66.7) 397 (57.8) 60 (57.1)
 T2 4 (33.3) 204 (28.1) 20 (34.5) 1 (33.3) 195 (28.4) 32 (30.5)
 T3 0 (0.0) 14 (1.9) 0 (0.0) 0 (0.0) 12 (1.8) 2 (1.9)
 T4 0 (0.0) 13 (1.8) 3 (5.2) 0 (0.0) 15 (2.2) 1 (1.00)
 Tx 2 (16.7) 69 (9.5) 7 (12.1) 0 (0.0) 68 (9.9) 10 (9.5)
N-stages [N (%)]
 N0 9 (75.0) 562 (77.5) 44 (75.9) 2 (66.7) 536 (78.0) 77 (73.3)
 N1 1 (8.3) 84 (11.6) 6 (10.3) 1 (33.3) 76 (11.1) 14 (13.3)
 N2 0 (0.0) 5 (0.7) 1 (1.7) 0 (0.0) 5 (0.7) 1 (1.0)
 N3 0 (0.0) 3 (0.4) 0 (0.0) 0 (0.0) 3 (0.4) 0 (0.0)
 Nx 2 (16.7) 71 (9.8) 7 (12.1) 0 (0.0) 67 (9.8) 13 (12.4)
M-stages [N (%)]
 M0 9 (75.0) 625 (86.2) 49 (84.5) 3 (100.0) 589 (85.7) 91 (86.7)
 M1 0 (0.0) 9 (1.2) 0 (0.0) 0 (0.0) 9 (1.3) 0 (0.0)
 Mx 3 (25.0) 91 (12.6) 9 (15.5) 0 (0.0) 89 (13.0) 14 (13.3)
ER-status [N (%)]
 Positive/negative 8 (66.7)/1 (8.3) 430 (59.3)/76 (10.5) 33 (56.9)/6 (10.3) 2 (66.7)/1 (33.3) 414 (60.3)/69 (10.0) 55 (52.4)/13 (12.4)
 Missing 3 (25.0) 219 (30.2) 19 (32.8) 0 (0.0) 204 (29.7) 37 (35.2)
HER2-status [N (%)]
 Positive/negative 0 (0.0)/3 (25.0) 14 (1.9)/126 (17.4) 0 (0.0)/8 (13.8) 0 (0.0)/0 (0.0) 11 (1.6)/123 (17.9) 3 (2.9)/14 (13.3)
 Missing 9 (75.0) 584 (80.7) 50 (86.2) 3 (100.0) 552 (80.5) 88 (83.8)
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information about the cancer diagnosis, time of death, and 
emigration.
A limitation of this study was that most of the study 
population had normal serum levels of vitamin B12 and 
folate and therefore the groups with abnormal levels were 
relatively small. The cancer subtype groups were particu-
larly affected by this and their case numbers became small. 
This made the interpretation harder and it may have con-
tributed to less statistical power. Another limitation was the 
lack of repeated measurements of folate and vitamin B12. 
Table 6  Hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations between vitamin B12, folate and BC severity groups
a BC cases were divided into three severity groups (good, moderate and severe) based on ER status, age at diagnosis and pTNM stage. Multivari-
ate models adjusted for age, education level, SES, CCI, serum glucose, triglycerides, cholesterol and fasting status
Total population 
N = 19,775
Vitamin B12 (pmol/L) p for trend Folate (nmol/L) p for trend
< 150 150–650 > 650 < 5 5–32 > 32
(n = 549) (n = 17,731) (n = 1,495) (n = 116) (n = 17,389) (n = 2,270)
BC
 N =795 12 725 58 3 687 105
 Crude HR 
(95% CI)
0.56 (0.32–1.00) 1.00 (Ref) 1.13 (0.86–1.47) 0.45 0.91 (0.29–2.81) 1.00 (Ref) 1.23 (1.00–1.50) 0.03
 Age-adjusted 
HR (95% CI)
0.55 (0.31–0.97) 1.00 (Ref) 0.98 (0.75–1.28) 0.77 0.90 (0.29–2.80) 1.00 (Ref) 1.09 (0.88–1.33) 0.26
 Multivariate 
adjusted HR 
(95% CI)
0.65 (0.29–1.46) 1.00 (Ref) 0.81 (0.53–1.24) 0.14 1.98 (0.49–7.94) 1.00 (Ref) 1.12 (0.85–1.48) 0.62
Severity  groupsa
 Good
  N = 412 6 381 25 2 359 51
  Crude HR 
(95% CI)
0.54 (0.24–1.21) 1.00 (Ref) 0.92 (0.61–1.38) 0.69 1.14 (0.29–4.59) 1.00 (Ref) 1.14 (0.85–1.53) 0.17
  Age-adjusted 
HR (95% 
CI)
0.53 (0.24–1.19) 1.00 (Ref) 0.84 (0.56–1.26) 0.93 1.14 (0.28–4.57) 1.00 (Ref) 1.06 (0.79–1.42) 0.39
  Multivariate 
adjusted 
HR (95% 
CI)
0.38 (0.09–1.52) 1.00 (Ref) 0.70 (0.39–1.26) 0.20 3.26 (0.81–
13.17)
1.00 (Ref) 1.03 (0.70–1.51) 0.60
 Moderate
  N = 148 1 137 10 1 128 19
  Crude HR 
(95% CI)
0.24 (0.03–1.75) 1.00 (Ref) 1.06 (0.56–2.02) 0.85 1.75 (0.24–
12.51)
1.00 (Ref) 1.19 (0.74–1.93) 0.46
  Age-adjusted 
HR (95% 
CI)
0.24 (0.03–1.70) 1.00 (Ref) 0.89 (0.47–1.69) 0.72 1.76 (0.25–
12.59)
1.00 (Ref) 1.02 (0.63–1.65) 0.93
  Multivariate 
adjusted 
HR (95% 
CI)
0.51 (0.07–3.65) 1.00 (Ref) 0.86 (0.34–2.12) 0.77 NA 1.00 (Ref) 0.96 (0.51–1.82) 0.42
 Severe
  N = 70 1 61 8 0 62 8
  Crude HR 
(95% CI)
0.56 (0.08–4.04) 1.00 (Ref) 1.82 (0.87–3.80) 0.44 NA 1.00 (Ref) 1.04 (0.50–2.16) 0.61
  Age-adjusted 
HR (95% 
CI)
0.55 (0.08–4.00) 1.00 (Ref) 1.71 (0.82–3.60) 0.54 NA 1.00 (Ref) 0.98 (0.47–2.05) 0.52
  Multivariate 
adjusted 
HR (95% 
CI)
1.27 (0.17–9.35) 1.00 (Ref) 1.04 (0.25–4.40) 0.52 NA 1.00 (Ref) 1.08 (0.38–3.09) 0.61
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It has been suggested that serum folate concentrations are 
sensitive to changes in dietary intake and that erythrocyte 
folate concentration may be a better indicator of folate 
concentrations in the long term. Using serum folate could 
therefore give a false picture of the folate status. Vitamin 
B12 concentrations have been shown to be more stable than 
folate concentrations, however, the literature on the stabil-
ity of both folate and vitamin B12 serum concentrations is 
sparse [57]. Furthermore, we lacked information about some 
potential confounding factors such as BMI, alcohol intake 
and smoking. We compensated this partly by adjusting for 
CCI, glucose, triglycerides, cholesterol and GGT instead. In 
addition, there were missing data for some of the variables, 
such as for fasting status. Finally, for BC we did not have 
sufficient information on the HER2 receptor status.
Conclusion
In contrast to previous studies, we found an inverse associa-
tion between high folate concentrations and high-risk PCa, 
suggesting that folate may be protecting against PCa devel-
opment and progression. We corroborated some previous 
findings suggesting no association between vitamin B12 
and BC risk; however, we found some positive association 
between high folate concentrations and BC risk in the fasting 
population which could suggest a role for folate in BC devel-
opment. Prospective studies with longitudinal measurements 
of both dietary intake and serum levels as well as detailed 
information on potential confounders and fasting status are 
needed to establish whether folate and vitamin B12 are sig-
nificant risk factors or have potential protective properties in 
the development of PCa and BC. This could help define new 
prevention targets and add information to the discussions of 
mandatory folate fortification.
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